Mark Krystal

8.7k citations

134 papers · 6.5k indexed · h-index 45

Virology top 0.5%
- HIV Research and Treatment 51
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 54
- HIV/AIDS Research and Interventions 18
Epidemiology top 0.5%
- Influenza Virus Research Studies 45
- Respiratory viral infections research 26
Immunology top 2%
- interferon and immune responses 16
Molecular Biology top 2%
- RNA and protein synthesis mechanisms 21
Genetics
- Virus-based gene therapy research 17

Co-authors: Peter Palese Jeffrey D. Parvin Nicholas A. Meanwell Christopher Cianci Masayoshi Enami Willem Luytjes Norman Arnheim Moira Hagen
Cited by: Virology Infectious Diseases Epidemiology
Journals: Bioorganic & Medicinal Chemistry Letters (21 papers)Journal of Virology (18 papers)Antimicrobial Agents and Chemotherapy (11 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Mark Krystal

132 papers receiving 6.3k citations

Peers

Countries citing papers authored by Mark Krystal

Since Specialization

Citations

This map shows the geographic impact of Mark Krystal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Krystal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Krystal more than expected).

Fields of papers citing papers by Mark Krystal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Krystal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Krystal. The network helps show where Mark Krystal may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Krystal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Krystal Line = papers co-authored together Mark Krystal links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exploring HIV-1 Maturation: A New Frontier in Antiviral Development Viruses ·Koksal Ceren,Alhussain Al Ajmi,par R. Cluzel,RenuS Bhardwaj,Hodach Ae,Robert Dickens,A Wuerz-Wessel,Andreas Kirchhoff,Austin Kruggel,Jiabao Shen,W. B. McKelvie,Kevin M. Peese,Samit R. Joshi,Mark Krystal,Kathleen DeCicco-Skinner,Eric O. Freed,Luca Sardo,T Izumi	2024	5
2	Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937 Viruses ·Brian McAuliffe,Sauro Valentini,Jie Chen,Yan Chen,Sing‐Yuen Sit,Jacob J. Swidorski,Richard A. Hartz,Li Xu,Brian L. Venables,Ny Sin,Nicholas A. Meanwell,Alicia Regueiro‐Ren,Susagna Argemí,Umesh Hanumegowda,Mark Krystal	2024	0
3	Improving Drug Delivery While Tailoring Prodrug Activation to Modulate C_max and C_min by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir Journal of Medicinal Chemistry ·Murugaiah A. M. Subbaiah,Md. Samar Ansari,F. M.H. Corstens,Xu Lanping,Sarmistha Halder Sinha,Sandhya Mandlekar,John F. Kadow,Susan Jenkins,Mark Krystal,Murali Subramanian,Srikanth Sridhar,AJ Ruppert-Kohlmayr,Priyadeep Bhutani,Anupam Kumar Singh,Nicholas A. Meanwell	2022	2
4	Synthesis, Structure–Activity Relationships, and In Vivo Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity Journal of Medicinal Chemistry ·Richard A. Hartz,Li Xu,Sing‐Yuen Sit,Jie Chen,Brian L. Venables,Zeyu Lin,Sharon Zhang,Zhufang Li,Dawn D. Parker,Hilary Pride,Susan Jenkins,Umesh Hanumegowda,Joshua Lider,Mark Krystal,Nicholas A. Meanwell,Alicia Regueiro‐Ren	2022	2
5	The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors Advances in experimental medicine and biology ·Tao Wang,John F. Kadow,Nicholas A. Meanwell,Mark Krystal	2022	2
6	(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration European Journal of Medicinal Chemistry ·Murugaiah A. M. Subbaiah,F. M.H. Corstens,Md. Samar Ansari,Xu Lanping,Sarmistha Halder Sinha,Sandhya Mandlekar,Mehdi Drissi Kaitouni,Mark Krystal,Murali Subramanian,Srikanth Sridhar,AJ Ruppert-Kohlmayr,Priyadeep Bhutani,Anupam Kumar Singh,John F. Kadow,Nicholas A. Meanwell	2020	5
7	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study PLoS ONE ·Joshua Lider,Sharon Zhang,Neelanjana Ray,Brett R. Beno,Alicia Regueiro‐Ren,Samit R. Joshi,Mark I. Cockett,Mark Krystal,Max Lataillade	2019	14
8	Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir Journal of Medicinal Chemistry ·Murugaiah A. M. Subbaiah,Nicholas A. Meanwell,John F. Kadow,Md. Samar Ansari,D Fanny,F. M.H. Corstens,Xu Lanping,Sarmistha Halder Sinha,Murali Subramanian,Sandhya Mandlekar,Srikanth Sridhar,AJ Ruppert-Kohlmayr,Priyadeep Bhutani,Anupam Kumar Singh,Mehdi Drissi Kaitouni,Mark Krystal,Chunfu Wang,Ramakanth Sarabu	2018	13
9	The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor Bioorganic & Medicinal Chemistry Letters ·B. Narasimhulu Naidu,Michael Walker,Margaret E. Sorenson,Yasutsugu Ueda,John D. Matiskella,Timothy P. Connolly,Ira B. Dicker,Zeyu Lin,Blanca Hernández,Brian Terry,Arne Lillelien,Ming Zheng,Dawn D. Parker,Dedong Wu,Stephen Adams,Mark Krystal,Nicholas A. Meanwell	2018	11
10	Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age The Pediatric Infectious Disease Journal ·Noris Pavía-Ruz,Gong Yong-he,Xavier Sáez‐Llorens,Torsak Bunupuradah,Ben Raderstorf,Rong Yang,Mohammad Wali-ul-Haq Ansari,Mark Krystal,Max Lataillade,Daniel Seekins,A. Lozano-Moreno	2015	4
11	Synthesis and evaluation of C2-carbon-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides as HIV-1 integrase inhibitors Bioorganic & Medicinal Chemistry Letters ·B. Narasimhulu Naidu,Margaret E. Sorenson,Manoj Patel,Yasutsugu Ueda,Jacques Banville,Françis Beaulieu,Blanca Hernández,Ira B. Dicker,Arne Lillelien,Zeyu Lin,Zhe Yu,Dawn D. Parker,Brian Terry,Ming Zheng,Alain Martel,Nicholas A. Meanwell,Mark Krystal,Michael Walker	2014	34
12	Respiratory syncytial virus fusion inhibitors. Part 7: Structure–activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo Bioorganic & Medicinal Chemistry Letters ·Ny Sin,Brian L. Venables,Keith D. Combrink,H. Belgin Gülgeze,Kuo‐Long Yu,Rita L. Civiello,Jan Willem Thuring,Jennifer M. Belcher,Zheng Yang,Lisa Zadjura,Anthony M. Marino,Kathleen F. Kadow,Christopher Cianci,Gaston Michel,Eugene V. Genovesi,Ivette Medina,Lucinda Lamb,Mark Krystal,Nicholas A. Meanwell	2009	36
13	Biochemical Analysis of HIV-1 Integrase Variants Resistant to Strand Transfer Inhibitors Journal of Biological Chemistry ·Ira B. Dicker,Brian Terry,Zeyu Lin,Zhufang Li,Blanca Hernández,Himadri Samanta,Nayomi Dayarathne,Michael Walker,Mark Krystal	2008	26
14	Triketoacid inhibitors of HIV-integrase: A new chemotype useful for probing the integrase pharmacophore Bioorganic & Medicinal Chemistry Letters ·Michael Walker,Timothy D. Johnson,Bethlehem Mengesha,Jacques Banville,Krishna Medepalli,Joseph Breton,Yunhui Zhang,Brandon K. Liew,Henry Ν. C. Wong,Albert Torri,Himadri Samanta,Zeyu Lin,Carol Deminie,Brian Terry,Mark Krystal,Nicholas A. Meanwell	2006	19
15	Differential effect of modified capped RNA substrates on influenza virus transcription Virus Research ·Christopher Cianci,Richard J. Colonno,Mark Krystal	1997	6
16	Inhibition of influenza viral polymerases by minimal viral RNA decoys. Journal of General Virology ·Guangxiang Luo,Van Der Merwe Wc,Mark Krystal	1997	10
17	Complementation and analysis of an NP mutant of influenza virus Virus Research ·Li Ruan,Peter Palese,Mark Krystal	1989	26
18	Expression of antisense RNA fails to inhibit influenza virus replication Virus Research ·Josef M.E. Leiter,Mark Krystal,Peter Palese	1989	17
19	The influenza c virus glycoprotein (HE) exhibits receptor-binding (hemagglutinin) and receptor-destroying (esterase) activities Virology ·Reinhard Vlasak,Mark Krystal,Mariana Nacht,Peter Palese	1987	111
20	Structure and evolution of human and African ape rDNA pseudogenes. Molecular Biology and Evolution ·Elise Brownell,Mark Krystal,Norman Arnheim	1984	25

About Mark Krystal

Mark Krystal is a scholar working on Virology, Infectious Diseases, Epidemiology, Hepatology and Immunology, having authored 134 papers that have together received 6.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (54 papers), HIV Research and Treatment (51 papers), Influenza Virus Research Studies (45 papers), Respiratory viral infections research (26 papers), RNA and protein synthesis mechanisms (21 papers), HIV/AIDS Research and Interventions (18 papers), Virus-based gene therapy research (17 papers) and interferon and immune responses (16 papers). The work is most often cited by research in Virology (981 citations), Infectious Diseases (1.9k citations), Epidemiology (3.3k citations), Immunology (1.0k citations) and Molecular Biology (2.7k citations). Mark Krystal has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Peter Palese, Jeffrey D. Parvin, Nicholas A. Meanwell, Christopher Cianci, Masayoshi Enami, Willem Luytjes, Norman Arnheim, Moira Hagen, Susumu Nakada and Laurence Tiley. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Virology, Antimicrobial Agents and Chemotherapy, Proceedings of the National Academy of Sciences and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact